Axial Therapeutics is developing gut-restricted small molecule therapies targeting the gut-brain axis to treat conditions such as irritability associated with autism spectrum disorder and Parkinson’s disease. Their lead candidate, AB-2004, is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in addressing these neurological disorders.
Funding
$102.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OUIFounders
Product
Problem
Many neurological disorders, such as autism spectrum disorder and Parkinson's disease, are influenced by the gut microbiome, yet effective therapies targeting this gut-brain axis are lacking. Current treatments often fail to address the underlying microbial contributions to these conditions.
Solution
Axial Therapeutics is developing a new class of gut-restricted small molecule therapies designed to modulate the gut microbiome and its impact on neurological health. Their Microbial-Inspired Therapeutics® platform identifies and targets specific microbial pathways implicated in diseases like autism spectrum disorder and Parkinson's disease. The lead candidate, AB-2004, is designed to reduce the levels of certain microbial metabolites in the gut that contribute to neurological symptoms. By selectively acting within the gastrointestinal tract, these therapies aim to minimize systemic exposure and potential side effects while maximizing therapeutic benefit through modulation of the gut-brain axis.
Target Audience
The primary target audience includes individuals with neurological disorders influenced by the gut microbiome, such as those with autism spectrum disorder and Parkinson's disease, as well as their caregivers and healthcare providers.
Features
- Gut-restricted small molecule design to minimize systemic exposure
- Microbial-Inspired Therapeutics® platform for identifying novel drug targets within the gut microbiome
- AB-2004, a lead candidate targeting specific microbial metabolites associated with irritability in autism spectrum disorder
- Pipeline programs in Parkinson's disease, liver disease, and oncology